SYGNATURE DISCOVERY
LIVE

Serial Number

79410216

Owner

Sygnature Discovery Limited

Attorney

Molly T. Eichten

Filing Date

Sep 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SYGNATURE DISCOVERY Trademark

Serial Number: 79410216 • Registration: 8097762

SYGNATURE DISCOVERY is a trademark filed by Sygnature Discovery Limited on September 12, 2024. The trademark is classified under Class 1 (Chemicals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Sygnature Discovery Limited (2 trademarks)

The Discovery Building Biocity,

Entity Type: 99

Trademark Details

Filing Date

September 12, 2024

Registration Date

January 13, 2026

Published for Opposition

November 25, 2025

Goods & Services

Proteins for industrial use; proteins for use in manufacture; proteins for use in scientific research; proteins for use in the manufacture of pharmaceutical products; protein in raw material form for material science, agritech, cosmeceutical research; protein in raw material form for industrial use; protein in raw material form for use in manufacture; protein in raw material form for use in scientific research; protein in raw material form for use in the manufacture of pharmaceutical products.

Scientific research and development services; drug discovery services; development of pharmaceutical preparations and medicines; drug screening for scientific research purposes; pharmaceutical drug development services; research and development of vaccines and medicines; research and development of human and veterinary pharmaceutical drugs; research relating to medicines; services for assessing the efficacy of human and veterinary pharmaceutical drugs, namely, human and veterinary pharmaceutical product evaluation, human and veterinary pharmaceutical drug discovery services; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to pharmaceutical research and developments; development of pharmaceutical preparations and medicines; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and drug development; research and development in the pharmaceutical and drug development fields; testing of pharmaceutical drugs; assay development services being custom design and development of biophysical, biochemical, cell-based, phenotypic, in-vitro and in-vivo, assays; biological research; biological analysis; biological research laboratory services; biological research, clinical research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases and medical research; consultancy relating to pharmacology; medical and pharmacological research services; scientific research for medical purposes in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; research in the field of synthetic biology; research and development in the field of microorganisms and cells; chemical research and analysis services; chemical engineering; chemistry services, namely, laboratory research in the field of chemistry; medicinal, synthetic, analytical and high throughput chemistry services, namely, hit generation and optimization, lead optimisation, scale up manufacture, metabolite, analogue, impurity, and analytical standard synthesis and/or isolation and purification, structure elucidation; clinical research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; organic chemistry research and analysis services; consultancy in the field of organic chemistry; laboratory research and analysis services in the field of organic chemistry; research and development services in the field of organic chemistry; development, testing and analysis of chemicals; development, testing and analysis of chemical production methods; protein and peptide mapping for scientific purposes; scientific analysis services, namely, scientific analysis of materials for human and veterinary pharmaceutical, material science, agritech, cosmeceutical research for scientific research purposes; protein analysis services for scientific purposes; scientific research in the field of protein sequencing; protein crystallisation screening for scientific purposes; quality control for others; testing of materials; product testing; technological research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; industrial analysis and research services in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; scientific services relating to cell line generation; scientific screening services being ion channel screening, iterative screening, fragment screening and in silico screening, for scientific research purposes; compound profiling and selectivity services; X-ray and cryoelectronmicroscopy imaging and NMR structure determination of proteins, biological macromolecules and molecules, other than for medical purposes; blood analysis services for scientific research purposes; information, advisory and consultancy services relating to the aforesaid services.

Processing of organic chemical liquids in the nature of chemical distillery services; recycling of organic solvents; purification of proteins; purification of proteins by chemical methods.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 6, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 18, 2026 FICS
FINAL DISPOSITION PROCESSED
Jul 18, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 7, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 20, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 20, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 13, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 13, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 13, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 27, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 24, 2025 TROA
REFUSAL PROCESSED BY IB
May 9, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 24, 2025 RFCS
REFUSAL PROCESSED BY MPU
Apr 24, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 14, 2025 RFCR
NON-FINAL ACTION WRITTEN
Mar 13, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 12, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 25, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 25, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 21, 2024 REPR